Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Le Palais des Congrès

Apr 13, 2015 9:00 AM - Apr 13, 2015 12:30 PM

2, Place de la porte Maillot, F-75017 Paris, France

EM06: MODELLING AND SIMULATION (M&S) / MODEL INFORMED DRUG DISCOVERY AND DEVELOPMENT (MID3)

Overview

The tutorial will be an opportunity to understand better the value of Modelling and Simulation (M&S) / Model Informed Drug Discovery and Development (MID3) in the development of new medicinal products, and the impact of MID3 on regulatory decision making and product labelling.
The tutorial will be divided in three parts.
First, the basic concepts and principles of modelling and simulation will be recalled and the added value over two stage approach will be discussed using examples.
The second part will be dedicated to the use of M&S and MID3 in the context of drug development and the impact it can have in key decision making: study design optimization, data analysis, dose selection and extrapolation will be discussed.
The last part will be dedicated to model evaluation given the purpose. For each of the application of M&S/MID3 in drug development, the relevant criteria for model evaluation will be presented and discussed. Focus will be made on data needed, model assumptions and uncertainties and fitting performances and examples will be provided for good and bad practices. Challenges in current practices (given the current regulatory requirements) will also be discussed.

Who should attend?

Modeller, biostatisticians, medical writers, clinical researchers, drug safety specialists, project managers, investigators, clinical practitioners, physicians, regulators, with basic experience/awareness of Modelling and Simulation (M&S)/Model Informed Drug Discovery and Development (MID3).

Learning objectives

At the conclusion of this tutorial, attendees will be able to:

  • Recall the basic concepts of Modelling and Simulation and its advantages over other approaches for Pharmacokinetics (PK) / Pharmacodynamcis (PD) description and predictions
  • Discuss/explain the added-value and importance of Modelling and Simulation Model Informed Drug Discovery and Development in the context of drug development
  • Outline/discuss the criteria for model evaluation given the purpose in drug development setting

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.